gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · PBYIHealthcarePharmaceuticals

PUMA BIOTECHNOLOGY INC (PBYI)

$10.69+4.60%
Close Nov 4, 2026 · split-adjusted
Nov 2, 2026$10.18▲ 101.98% in range
Nov 3, 2025Low $4.73 · High $11.26Nov 2, 2026
What changed · written from our data
As of Nov 4, 2026

PUMA BIOTECHNOLOGY closed at $10.69 on Nov 4, up 4.60%, 5.1% below its 52-week closing high. Volume of 475.2K shares was 1.31× its 20-day average (above normal).

Split-adjusted performance: +12.5% over one month, +43.5% over six months, +112.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $56.50M, up 7.8% from a year earlier, with a net margin of 14.5%.

Short interest was 4.5M shares at the Oct 15 settlement, up 6.5% from the prior report (11.6% of float, 12.9 days to cover).

Market cap$551.8M51.6M shares
Revenue · quarter$56.5M+7.8% YoY
Diluted EPS$0.16+33.3% YoY
P/E · TTM20.7×P/S 2.4×
Net margin14.5%Gross 77.9%
Dividend yieldNone
52-week range4.73 – 11.26−5.1% from high
Volume475.2K1.31× 20-day avg
Volatility · 60d40.4%Annualised
Short % of float11.6%12.9 days to cover
Net cash$93.9MCash $93.9M
Next earnings—Not scheduled
Split-adjusted performance
1W +0.7%1M +12.5%3M +31.7%6M +43.5%YTD +79.7%1Y +112.1%3Y +325.9%5Y +104.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum91
Revenue growth53
Net margin82
Value (low P/E)40
Size63

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short4.5M+6.5% vs prior
Days to cover12.9Settled Oct 15
% of float11.6%
Short vol. 10d54.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
PBYIPUMA BIOTECHNOLOGY$10.69+4.60%+43.5%+7.8%14.5%20.7$551.8M
NGNENeurogene$27.58+3.41%−14.7%———$551.9MCompare
CLYMClimb Bio$9.33−4.31%−23.6%———$535.9MCompare
OVIDOvid Therapeutics$2.74+14.17%−1.4%−88.3%−2047.6%—$535.1MCompare
ACRSAclaris Therapeutics$3.68−1.60%−23.0%−8.3%−1320.1%—$570.3MCompare
DMACDiaMedica Therapeutics$10.77+7.70%+65.2%———$580.8MCompare
CAPRCapricor Therapeutics$8.92+8.25%−74.1%———$518.6MCompare
BCAXBicara Therapeutics$8.89−0.78%−62.6%———$588.3MCompare
STTKShattuck Labs$5.15−5.85%−22.9%———$516.9MCompare

News about PUMA BIOTECHNOLOGY

All news →
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema OncologyZacks Investment Research · Oct 19, 2026Neutral

Quick answers

What does PUMA BIOTECHNOLOGY do?
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer.
What is PBYI's market cap?
$551.82M, based on the Nov 4 close of $10.69.
What is PBYI's P/E ratio?
20.7× trailing-twelve-month earnings of $26.72M.
Does PUMA BIOTECHNOLOGY pay a dividend?
No regular cash dividend has been paid in the last year.
How much of PBYI is sold short?
4.5M shares, 11.6% of float, as of Oct 15, 2026.
What sector is PBYI in?
Healthcare, in the Pharmaceuticals industry.

About PUMA BIOTECHNOLOGY

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

HQ: Los Angeles, CA179 employeesListed Mar 21, 2012pumabiotechnology.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology